Telix Pharmaceuticals
Telix Pharmaceuticals Limited, commonly referred to as Telix, is a pioneering biopharmaceutical company headquartered in the United States, with significant operations across Europe and Asia-Pacific. Founded in 2015, Telix focuses on the development of innovative radiopharmaceuticals for the diagnosis and treatment of cancer, particularly in areas such as prostate and kidney cancers. The company’s core products, including its lead candidate TLX591 (also known as Illuccix), utilise advanced radiolabelled technologies that enhance precision in cancer imaging and therapy. Telix has established a strong market position, marked by notable achievements such as successful clinical trials and strategic partnerships that bolster its research and development capabilities. With a commitment to improving patient outcomes, Telix Pharmaceuticals is at the forefront of the evolving landscape of oncology therapeutics.
DitchCarbon Score
How does Telix Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Telix Pharmaceuticals's score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Telix Pharmaceuticals's reported carbon emissions
Telix Pharmaceuticals, headquartered in the US, currently does not have publicly available data on its carbon emissions, as there are no reported figures for emissions in kg CO2e. Additionally, there are no specified reduction targets or climate pledges outlined in their initiatives. In the absence of specific emissions data, it is important to note that many companies in the pharmaceutical industry are increasingly focusing on sustainability and climate commitments. This often includes setting science-based targets for emissions reductions and implementing strategies to minimise their carbon footprint across all scopes of emissions (Scope 1, 2, and 3). As Telix Pharmaceuticals continues to develop its sustainability strategy, stakeholders may look for future commitments and initiatives aimed at addressing climate change and reducing environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Telix Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
